C
인투셀
287840KOSDAQ41.5 / 100
Reference Date: 2026-10-23
Financial Score9.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 2.9% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
IntuCell is an ADC platform technology company specializing in linker and drug development, leveraging its OHPAS linker and PMT platform technologies to enhance drug delivery efficiency and selectivity. The company utilizes proprietary drug technologies such as Duocarmycin and Nexatecan to establish a competitive edge in oncology, with a pipeline including the B7-H3-targeting ADC candidate ITC-6146RO.
Number of Employees
—
Average Salary
—
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
10.19Industry Average 1.200.0Point
8.5x industry avg (risky)
ROE
-65.72Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
53.66Industry Average 100.005.0Point
Lower than industry avg (good)
Trend 2024~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼20.9% (1-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼5.2% (1-year basis)
ROE Trend
0.0 / 4
Avg ROE -80.6% (improving, 2yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (5%, downtrend)
Current 16,790Won52-week high 71,00052-week low 13,390
1-month return4.0Point
1m +2.94% (slight rise)
Volume trend5.0Point
Volume increasing
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0